159 related articles for article (PubMed ID: 30032829)
1. Synchronous primary lung adenocarcinomas harboring distinct MET Exon 14 splice site mutations.
Wang SXY; Lei L; Guo HH; Shrager J; Kunder CA; Neal JW
Lung Cancer; 2018 Aug; 122():187-191. PubMed ID: 30032829
[TBL] [Abstract][Full Text] [Related]
2. Response to MET inhibitors in patients with stage IV lung adenocarcinomas harboring MET mutations causing exon 14 skipping.
Paik PK; Drilon A; Fan PD; Yu H; Rekhtman N; Ginsberg MS; Borsu L; Schultz N; Berger MF; Rudin CM; Ladanyi M
Cancer Discov; 2015 Aug; 5(8):842-9. PubMed ID: 25971939
[TBL] [Abstract][Full Text] [Related]
3. Molecular Testing in Multiple Synchronous Lung Adenocarcinomas: Case Report and Literature Review.
Rafael OC; Lazzaro R; Hasanovic A
Int J Surg Pathol; 2016 Feb; 24(1):43-6. PubMed ID: 26350052
[TBL] [Abstract][Full Text] [Related]
4. Next-generation sequencing facilitates differentiating between multiple primary lung cancer and intrapulmonary metastasis: a case series.
Liu C; Liu C; Zou X; Shao L; Sun Y; Guo Y
Diagn Pathol; 2021 Mar; 16(1):21. PubMed ID: 33706781
[TBL] [Abstract][Full Text] [Related]
5. MET exon 14 mutations as targets in routine molecular analysis of primary sarcomatoid carcinoma of the lung.
Saffroy R; Fallet V; Girard N; Mazieres J; Sibilot DM; Lantuejoul S; Rouquette I; Thivolet-Bejui F; Vieira T; Antoine M; Cadranel J; Lemoine A; Wislez M
Oncotarget; 2017 Jun; 8(26):42428-42437. PubMed ID: 28418914
[TBL] [Abstract][Full Text] [Related]
6. Comprehensive genomic profiling aids in understanding the lesion origins of a patient with six synchronous invasive lung adenocarcinomas: a case study.
Song Y; Jia Z; Wu P; Wang W; Ou Q; Bao H; Yu M; Wu X; Liu P; Liang N; Zhang S; Li S
BMC Pulm Med; 2020 Apr; 20(1):80. PubMed ID: 32245453
[TBL] [Abstract][Full Text] [Related]
7. Morphological and genetic heterogeneity in multifocal lung adenocarcinoma: The case of a never-smoker woman.
Bonanno L; Calabrese F; Nardo G; Calistri D; Tebaldi M; Tedaldi G; Polo V; Vuljan S; Favaretto A; Conte P; Amadori A; Rea F; Indraccolo S
Lung Cancer; 2016 Jun; 96():52-5. PubMed ID: 27133750
[TBL] [Abstract][Full Text] [Related]
8. MET exon 14 skipping mutation in triple-negative pulmonary adenocarcinomas and pleomorphic carcinomas: An analysis of intratumoral MET status heterogeneity and clinicopathological characteristics.
Kwon D; Koh J; Kim S; Go H; Kim YA; Keam B; Kim TM; Kim DW; Jeon YK; Chung DH
Lung Cancer; 2017 Apr; 106():131-137. PubMed ID: 28285687
[TBL] [Abstract][Full Text] [Related]
9. Next-Generation Sequencing: A Novel Approach to Distinguish Multifocal Primary Lung Adenocarcinomas from Intrapulmonary Metastases.
Patel SB; Kadi W; Walts AE; Marchevsky AM; Pao A; Aguiluz A; Mudalige T; Liu Z; Deng N; Lopategui J
J Mol Diagn; 2017 Nov; 19(6):870-880. PubMed ID: 28866070
[TBL] [Abstract][Full Text] [Related]
10. Molecular Diagnostic Assays and Clinicopathologic Implications of MET Exon 14 Skipping Mutation in Non-small-cell Lung Cancer.
Kim EK; Kim KA; Lee CY; Kim S; Chang S; Cho BC; Shim HS
Clin Lung Cancer; 2019 Jan; 20(1):e123-e132. PubMed ID: 30391211
[TBL] [Abstract][Full Text] [Related]
11. Identification of MET exon14 skipping by targeted DNA- and RNA-based next-generation sequencing in pulmonary sarcomatoid carcinomas.
Li Y; Gao L; Ma D; Qiu T; Li W; Li W; Guo L; Xing P; Liu B; Deng L; Fu J; Li J; Yu Y; Ying J
Lung Cancer; 2018 Aug; 122():113-119. PubMed ID: 30032818
[TBL] [Abstract][Full Text] [Related]
12. Breast cancer and synchronous multiple primary lung adenocarcinomas with heterogeneous mutations: a case report.
Jin B; Zhang S; Chuang X; Yu P; Chen Y; Teng Y; Che X; Fan Y; Zheng C; Li X; Qiu X; Qu X; Liu Y
BMC Cancer; 2018 Nov; 18(1):1138. PubMed ID: 30453894
[TBL] [Abstract][Full Text] [Related]
13. [Multiple synchronous lung adenocarcinoma: Interest of molecular biology for staging].
Boukhiar S; Tiffet O; Bayle-Bleuez S; Picot T; Yvorel V; Forest F
Rev Mal Respir; 2021 Nov; 38(9):942-945. PubMed ID: 34565641
[TBL] [Abstract][Full Text] [Related]
14. Characterization of 298 Patients with Lung Cancer Harboring MET Exon 14 Skipping Alterations.
Schrock AB; Frampton GM; Suh J; Chalmers ZR; Rosenzweig M; Erlich RL; Halmos B; Goldman J; Forde P; Leuenberger K; Peled N; Kalemkerian GP; Ross JS; Stephens PJ; Miller VA; Ali SM; Ou SH
J Thorac Oncol; 2016 Sep; 11(9):1493-502. PubMed ID: 27343443
[TBL] [Abstract][Full Text] [Related]
15. Clinicopathology and genetic profile of synchronous multiple small adenocarcinomas: implication for surgical treatment of an uncommon lung malignancy.
Lin MW; Wu CT; Kuo SW; Chang YL; Yang PC
Ann Surg Oncol; 2014 Aug; 21(8):2555-62. PubMed ID: 24643899
[TBL] [Abstract][Full Text] [Related]
16. Activation of MET by gene amplification or by splice mutations deleting the juxtamembrane domain in primary resected lung cancers.
Onozato R; Kosaka T; Kuwano H; Sekido Y; Yatabe Y; Mitsudomi T
J Thorac Oncol; 2009 Jan; 4(1):5-11. PubMed ID: 19096300
[TBL] [Abstract][Full Text] [Related]
17. Next-Generation Sequencing of Pulmonary Sarcomatoid Carcinoma Reveals High Frequency of Actionable MET Gene Mutations.
Liu X; Jia Y; Stoopler MB; Shen Y; Cheng H; Chen J; Mansukhani M; Koul S; Halmos B; Borczuk AC
J Clin Oncol; 2016 Mar; 34(8):794-802. PubMed ID: 26215952
[TBL] [Abstract][Full Text] [Related]
18. MET exon 14 skipping mutations and gene amplification in a Taiwanese lung cancer population.
Lung J; Hung MS; Lin YC; Lee KF; Jiang YY; Huang SL; Fang YH; Lu MS; Lin CK; Yang TM; Lin PY; Hsieh MJ; Tsai YH
PLoS One; 2019; 14(8):e0220670. PubMed ID: 31369639
[TBL] [Abstract][Full Text] [Related]
19. A never-smoker lung adenocarcinoma patient with a MET exon 14 mutation (D1028N) and a rapid partial response after crizotinib.
Mahjoubi L; Gazzah A; Besse B; Lacroix L; Soria JC
Invest New Drugs; 2016 Jun; 34(3):397-8. PubMed ID: 26892698
[TBL] [Abstract][Full Text] [Related]
20. Diagnosis of synchronous primary lung adenocarcinomas based on epidermal growth factor (EGFR) gene status: A case report.
Takuwa T; Tanaka F; Yoneda K; Torii I; Hashimoto M; Okumura Y; Matsumoto S; Kondo N; Hasegawa S
Lung Cancer; 2010 Jun; 68(3):498-500. PubMed ID: 20307913
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
